No meaningful insider selling pressure detected. The CEO's significant option exercises may signal confidence in holding, not exiting. Monitor for follow-on open-market selling or changes in sentiment ahead of earnings.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 27 $501.29entry
- T+1 · 9mo ago +1.90%α +1.85% · $510.82
- T+5 · 9mo ago −5.14%α −3.16% · $475.52
- T+20 · 8mo ago +4.29%α +11.84% · $522.78
- T+60 · 6mo ago +15.39%α +6.00% · $578.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A recent insider trading cluster at United Therapeutics shows CEO Martine Rothblatt exercising options for nearly $2.8M in shares, while two other insiders conducted small open-market sales totaling $127K. The majority of activity consists of derivative exercises, not open-market selling.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt exercised derivatives for 19,000 shares valued at $2,774,570 across two transactions on March 2 and 3, 2026.
- Two open-market sales occurred: Malcolm Jan sold $25,460 worth of shares and Judy Olian sold $101,910 worth.
- Total open-market selling in the cluster: $127,370, consistent with recent 30-day insider activity.
- Derivative exercises (M-coded transactions) are non-cash events and do not represent shares sold into the market.
- Total insider open-market selling represents only 0.0006% of $21.5B market cap, immaterial in scale.
Financial Impact
$127,370 in open-market sales and $2.77M in derivative exercises (non-cash)
Risk Factors
- Perception risk: Large derivative exercise by CEO could be misinterpreted as selling, though shares were not sold.
- Minor open-market dispositions could signal portfolio rebalancing, but not alarmingly so.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (5 trades, 7d window) | cluster-UTHR-1772746519231 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers